KRAS G12V (Q28371388)

From Wikidata

Jump to navigation Jump to search

genetic variant

GLY12VAL
G12V
RS121913529

Language	Label	Description	Also known as
English	KRAS G12V	genetic variant	GLY12VAL G12V RS121913529

Statements

missense mutation

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

25398284

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

25398284

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

biological variant of

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

positive therapeutic predictor for

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

CIViC 1-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/795

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

negative therapeutic predictor for

medical condition treated

statement disputed by

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1715

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2268

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/136

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/6323

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/6323

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/3924

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2219

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/3824

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

negative prognostic predictor for

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/987

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

Identifiers

CIViC variant ID

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_004985.4:c.35G>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

NP_004976.2:p.Gly12Val

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

NC_000012.11:g.25398284C>A

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

ENST00000256078.4:c.35G>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/425

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371388&oldid=2014799228"